Alpha¹ by KaimenConfidential

Kaimen Rigor review

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

DOI: 10.1038/s41591-025-04169-6
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/7d9e8c25-94ca-4524-ac1b-04204cad5229 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

1.75 / 5

Critical — serious problems across many checks

Mixed Methods

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on reductions in plasma triglycerides and remnant cholesterol, which are surrogate biomarkers for cardiovascular risk, not hard clinical outcomes. The paper does not provide evidence linking these surrogate reductions to clinical outcomes such as cardiovascular events, nor does it demonstrate target engagement at the tested dose in humans beyond showing reductions in ApoC3 and ANGPTL3, which are mechanistic biomarkers. The phase 1 trial is exploratory with no hard endpoints.
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol (secondary endpoints)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes are percentage reductions in surrogate lipid parameters (e.g., TG, RC) without anchoring to a minimal clinically important difference or clinical outcome. The paper acknowledges the exploratory nature and healthy volunteer population, and the reductions are not compared to established thresholds for clinical benefit.
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT06564584 was first submitted to ClinicalTrials.gov on 2024-08-19, after the registered study start date of 2024-08-12. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT06564584
reviewer’s wording
04Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Cell line "HepG2" is on the ICLAC register (CURATED-0001) as misidentified (Liver, hepatoblastoma), not Liver, hepatocellular carcinoma. Results attributed to this line may describe a different cell type unless the stock was authenticated (e.g. STR profiling). Used here: "1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c"
“1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a well-conceived and transparently reported mixed-methods study combining preclinical, genetic, and phase 1 clinical data to evaluate a liver-restricted LXR inverse agonist. Major strengths include a strong scientific premise, clear ethical approvals for the clinical trial, and good data availability. Key weaknesses are incomplete reporting of preclinical randomization/blinding/power, missing cell line authentication and mycoplasma testing (including a misidentified HepG2 line), and imprecise p-value reporting in some figures.

Both reviewers classified the study as mixed; no divergence. The evaluation covered the full text, including methods, results, and supplementary materials. The statistics verification component checked 0 tests (none recomputable from reported statistics), so statistical correctness beyond the reported tests is unverified. The citation check found no retracted or unresolved references. The integrity check flagged a misidentified cell line and a retrospective trial registration, which are incorporated into the relevant dimensions.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

lowinternal contradiction
The abstract states 'up to 38.5%' reduction in TG, but Table 1 shows -38.5% for 12 mg and -37.6% for 6 mg; the abstract's 'up to' is consistent, but the 61% reduction in RC is only for postprandial RC at 12 mg, which is not clearly stated in the abstract.
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol”
Table 1Find in source

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

supportedReviewers 1, 2
TLC-2716 is well tolerated in healthy participants after 14 days of treatment.
The phase 1 trial reported no serious adverse events and all AEs were mild except one moderate unrelated event, supporting tolerability.
Evidence: Results section: 'No clinically notable changes in vital signs or safety laboratory and electrocardiogram parameters, deaths, serious adverse events (AEs) or discontinuations of study medication were reported.'
“TLC-2716 was well tolerated in this phase 1 study”
ResultsFind in source
supportedReviewer 1
TLC-2716 reduces plasma triglycerides and remnant cholesterol in humans.
The trial showed statistically significant placebo-adjusted reductions in TG and RC at 6 and 12 mg doses, supporting the claim.
Evidence: Table 1 shows placebo-adjusted percentage changes in TG of -37.6% (p=0.003) and -38.5% (p=0.024) for 6 and 12 mg, and RC reductions of -33.5% and -29.5% (predose) and -59.2% and -61.0% (postprandial).
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol”
ResultsFind in source
supportedReviewers 1, 2
TLC-2716 is liver- and gut-restricted, avoiding systemic LXR inhibition.
PK data show low plasma exposure and high liver/ileum exposure, and no effect on ABCA1/ABCG1 in PBMCs, supporting the claim.
Evidence: Results: 'TLC-2716 did not reduce the expression of either of these genes' (ABCA1/ABCG1) and PK data showing low Cmax.
“TLC-2716 acts primarily in the liver and intestine and does not inhibit LXR activity in white blood cells”
ResultsFind in source
supportedReviewers 1, 2
LXR inverse agonists improve insulin sensitivity in rodents.
Hyperinsulinemic-euglycemic clamp studies in DIO mice showed improved glucose infusion rate with TLC-6665, and ZDF rats showed reduced fasting glucose with TLC-2716.
Evidence: Extended Data Fig. 5 shows GIR and HGP data; Results: 'The glucose infusion rate was higher in mice on TLC-6665 than in those treated with vehicle'.
“LXR inverse agonists hence improve insulin sensitivity in dysmetabolic rodents.”
ResultsFind in source
supportedReviewers 1, 2
TLC-2716 reduces lipid accumulation and inflammation in human liver organoids.
sHLO experiments showed dose-dependent reduction in lipid content and suppression of inflammatory/fibrotic gene expression, supporting the claim.
Evidence: Results: 'TLC-2716 dose dependently reduced intracellular lipid content in sHLOs' and GSEA showed suppression of inflammation and fibrosis gene sets.
“TLC-2716 dose dependently reduced intracellular lipid content in sHLOs”
ResultsFind in source
supportedReviewer 2
TLC-2716 reduces plasma triglycerides and remnant cholesterol in healthy participants.
Table 1 shows significant placebo-adjusted reductions in TG and RC at 6 and 12 mg doses.
Evidence: Table 1: placebo-adjusted percentage changes in TG -37.6% (6 mg) and -38.5% (12 mg); RC -33.5% and -29.5% predose.
Placebo-adjusted median percentage changes in TG from day 1 to day 14 were −37.6% (95% CI, −54.0 to −19.9) with 6 mg and −38.5% (95% CI, −67.9 to −7.2) with 12 mg
Table 1reviewer’s wording

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on reductions in plasma triglycerides and remnant cholesterol, which are surrogate biomarkers for cardiovascular risk, not hard clinical outcomes. The paper does not provide evidence linking these surrogate reductions to clinical outcomes such as cardiovascular events, nor does it demonstrate target engagement at the tested dose in humans beyond showing reductions in ApoC3 and ANGPTL3, which are mechanistic biomarkers. The phase 1 trial is exploratory with no hard endpoints.
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol (secondary endpoints)”
Find in source
INADEQUATEEffect size
The reported effect sizes are percentage reductions in surrogate lipid parameters (e.g., TG, RC) without anchoring to a minimal clinically important difference or clinical outcome. The paper acknowledges the exploratory nature and healthy volunteer population, and the reductions are not compared to established thresholds for clinical benefit.
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol”
Find in source

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

3 integrity concerns flagged (0 high).

mediumother
Trial NCT06564584 was first submitted to ClinicalTrials.gov on 2024-08-19, after the registered study start date of 2024-08-12. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT06564584
reviewer’s wording
mediumother
Cell line "HepG2" is on the ICLAC register (CURATED-0001) as misidentified (Liver, hepatoblastoma), not Liver, hepatocellular carcinoma. Results attributed to this line may describe a different cell type unless the stock was authenticated (e.g. STR profiling). Used here: "1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c"
“1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c”
Find in source

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions5 pass · 3 warn

The introduction thoroughly reviews prior research on LXR biology, dyslipidemia, and the rationale for LXR inverse agonists, including strengths and limitations of previous approaches. The hypothesis follows logically from the cited evidence, and the paper addresses limitations of prior LXR agonists (e.g., systemic effects on RCT) by developing a liver-restricted compound.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific premise is well established with extensive prior work cited and a clear rationale linking LXR biology to dyslipidemia and the development of TLC-2716.

Evidence

“The liver X receptors (LXRs; LXRα (encoded by NR1H3 ) and LXRβ (encoded by NR1H2 )) are members of the nuclear hormone receptor superfamily and key transcriptional regulators of systemic lipid metabolism”

Introduction ¶1Find in source

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

Introduction ¶4Find in source

“Here, we leveraged human genetic data, dysmetabolic rodent models, humanized experimental models, toxicology studies and a phase 1 clinical trial to evaluate the tolerability and efficacy of TLC-2716”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The scientific premise is well established with extensive prior work cited and a clear rationale linking LXR biology to dyslipidemia and the development of TLC-2716.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“LXR activation increases liver and plasma TG and LDL-C in animal models and humans by upregulating DNL genes... By contrast, repression of LXR activity in the liver reduces hepatic DNL and, consequently, plasma and liver TG and improves hypertriglyceridemia and related comorbidities in preclinical models.”

paraphrase[Introduction, paragraph 3]

“Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport (RCT)... Here, we leveraged human genetic data, dysmetabolic rodent models, humanized experimental models, toxicology studies and a phase 1 clinical trial to evaluate the tolerability and efficacy of TLC-2716, an orally administered LXR inverse agonist.”

The phase 1 trial reports randomization (8:2 per dose) and is described as placebo-controlled, but blinding is not explicitly stated. The preclinical animal studies do not report randomization methods, blinding, or a priori power calculations. Inclusion/exclusion criteria are well-defined for the clinical trial, and the statistical analysis section states no formal power calculation was used. Outlier handling is addressed via non-parametric methods (Hodges-Lehmann estimator).

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsNOT REPORTED

outlier handlingADEQUATE

randomization unitINADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionINADEQUATE

independent replicationINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The clinical trial is well-designed with randomization and blinding, but the preclinical studies lack explicit randomization, blinding, and power analysis details.

Evidence

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

absence[Methods, Preclinical studies (not explicitly detailed in the provided text)]

Preclinical studies do not report randomization or blinding methods.

WARNReviewer 2· 85% conf

The clinical trial is well-designed with randomization and blinding, but the preclinical studies lack explicit randomization, blinding, and power analysis details.

Evidence

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

paraphrase[Methods, Preclinical studies (inferred from figure legends)]

“Paraphrase: Preclinical experiments report n per group but do not describe randomization or blinding procedures.”

Preclinical studies report sex (e.g., male DIO mice, male and female NHPs), age/weight (e.g., young, lean), and species/strain (e.g., CD-1 mice, cynomolgus monkeys). Housing conditions are not explicitly described. The clinical trial reports demographics (age range, BMI, sex) and health status (healthy volunteers).

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedINADEQUATE

age weight healthADEQUATE

housing conditionsNOT REPORTED

species strain sourceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Biological variables are well reported for both preclinical and clinical components, including sex, age, and health status.

Evidence

paraphrase[Results, TLC-2716 has a favorable therapeutic index...]

“TLC-2716 was administered orally at 1, 5 and 15 mg per kg (body weight) per day ... for 28 days to young, lean male and female NHPs.”

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m −2”

MethodsFind in source

absence[Methods, Preclinical studies]

Housing conditions for animals are not reported.

PASSReviewer 2· 80% conf

Biological variables are well reported for both preclinical and clinical components, including sex, age, and health status.

Evidence

paraphrase[Methods, Preclinical toxicology; Methods, Phase 1 clinical trial]

“TLC-2716 was administered orally at 1, 5 and 15 mg per kg (body weight) per day ... to young, lean male and female NHPs.”

paraphrase[Methods, Phase 1 clinical trial, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2”

The clinical trial protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858), and written informed consent was obtained. Regulatory compliance is stated (conducted in accordance with relevant local regulatory policies). Preclinical studies do not explicitly mention IACUC approval, but this is a common omission in such papers; however, the absence is noted.

Sub-criteria

iacuc statementNOT REPORTED

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented for the clinical trial, including a named ethics committee and informed consent.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

absence[Methods, Preclinical studies]

IACUC approval for animal studies is not explicitly stated.

PASSReviewer 2· 95% conf

Ethical approvals are clearly documented for the clinical trial, including a named ethics committee and informed consent.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

The investigational product TLC-2716 is named with patent reference and dosing, which is adequate. However, antibodies used in assays are not identified with catalog numbers, cell lines (e.g., Upcyte hepatocytes, iPS cells) lack authentication details, and mycoplasma testing is not mentioned. Software tools are identified (e.g., R packages, STAR, Limma). Cell line "HepG2" is on the ICLAC register (CURATED-0001) as misidentified (Liver, hepatoblastoma), not Liver, hepatocellular carcinoma. Results attributed to this line may describe a different cell type unless the stock was authenticated (e.g. STR profiling). Used here: "1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c"

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedADEQUATE

antibodies identifiedNOT REPORTED

cell line authenticationNOT REPORTED

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

Key resources are partially identified; the investigational drug is well described, but antibodies, cell lines, and mycoplasma testing are not fully detailed.

Evidence

“TLC-2716 (ref. ) and its analog TLC-6665 (ref. ) are two LXR inverse agonists. Information on these compounds is available in patent US11970484B2”

ResultsFind in source

absence[Methods, Preclinical studies]

Antibodies used are not identified with catalog numbers.

“The voom function of the Limma R package (version 3.60.0) was applied”

MethodsFind in source

WARNReviewer 2· 80% conf

Key resources are partially identified; the investigational product is described, but antibodies, cell lines, and reagents are not fully specified.

Evidence

“TLC-2716 (ref. ) and its analog TLC-6665 (ref. ) are two LXR inverse agonists. Information on these compounds is available in patent US11970484B2”

ResultsFind in source

paraphrase[Methods, Cell culture (inferred)]

“Paraphrase: Upcyte hepatocytes and iPS-derived organoids are used but STR authentication is not mentioned.”

Tests are named (e.g., Mann-Whitney U, Wilcoxon signed-rank, two-way ANOVA). Assumptions are addressed via non-parametric methods. Exact p-values are often reported as thresholds (e.g., P < 0.05) rather than exact values. Effect sizes with confidence intervals are provided for the clinical trial (e.g., Hodges-Lehmann estimates with 95% CI). Software is identified. Data presentation includes box plots and dot plots with per-group n. Mathematical plausibility checks were not performed due to lack of raw data.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are well described, with named tests, effect sizes with confidence intervals, and appropriate handling of skewed data.

Evidence

“For analyses of changes from baseline, two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U -tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

Statistical analysisFind in source

“P value versus placebo b | — | 0.281 | 0.681 | 0.003 | 0.024”

Table 1Find in source

“Given the skewed distribution of plasma lipid data, we applied the Hodges–Lehmann estimator”

Statistical analysisFind in source

WARNReviewer 2· 85% conf

Statistical methods are generally well described, but exact p-values are often not reported (only thresholds), and some analyses lack effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical analyses]

“two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U-tests (for comparisons between groups) were used”

“Adjusted P values are indicated; N = 216 individuals in total.”

Figure 1DFind in source

The data availability statement provides a concrete route for clinical data (on reasonable request with detailed conditions) and deposits HLO RNA-seq data in GEO (GSE299888). Preclinical raw data are available in Source Data. Code availability states no original code was generated.

Sub-criteria

code sharingN/A

accession numbersADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is well addressed with a clear statement, repository deposits for RNA-seq data, and a managed-access procedure for clinical data.

Evidence

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research aligned with the original scope of the trial.”

Data availabilityFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

“This study did not generate original code.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is well described with a clear access mechanism for clinical data and a GEO accession for RNA-seq data; code is not applicable.

Evidence

Data availabilityFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

The clinical trial is registered (NCT05483998), and a CONSORT flow diagram is provided. Methods are detailed enough for replication. Limitations are discussed (e.g., healthy volunteers, exploratory endpoints). Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, CONSORT flow diagram, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Flow diagram for the CONSORT of the TLC-2716 phase 1 clinical trial.”

Figure 4Find in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, CONSORT flow diagram, and discussion of limitations.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

ClinicalTrials.gov

NCT05483998

ClinicalTrials.gov

NCT06564584

Reporting guidelines: CONSORT

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 74 references by DOI: 1 verified — 73 no DOI (shown, not verified).

NO DOI
Issues in hypertriglyceridemic pancreatitis—an update
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population-based study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mechanism of action of fibrates on lipid and lipoprotein metabolism
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An oxysterol signalling pathway mediated by the nuclear receptor LXR
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Preliminary crystallographic analysis of murine macrophage inflammatory protein 2
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Role of LXRs in control of lipogenesis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipogenesis inhibitors: therapeutic opportunities and challenges
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Unravelling high density lipoprotein–apolipoprotein metabolism in human mutants and animal models
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Antihyperlipidemic activity of gut-restricted LXR inverse agonists
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Inhibition of hepatotoxicity by a LXR inverse agonist in a model of alcoholic liver disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety, pharmacokinetics, and lipid lowering effects of the oral, liver-targeted liver X receptor (LXR) inverse agonist TLC-2716 in healthy volunteers
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Exome sequencing and analysis of 454,787 UK Biobank participants
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The UK Biobank resource with deep phenotyping and genomic data
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
FinnGen provides genetic insights from a well-phenotyped isolated population
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Million Veteran Program: a mega-biobank to study genetic influences on health and disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An integrated systems genetics and omics toolkit to probe gene function
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Genotype–Tissue Expression (GTEx) project
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mapping the genetic architecture of gene expression in human liver
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
LXR modulators with bicyclic core moiety
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A novel animal model of nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Near completely humanized liver in mice shows human-type metabolic responses to drugs
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An intronic variant in the GCKR gene is associated with multiple lipids
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Association of baseline characteristics with insulin sensitivity and β-cell function in the Glycemia Reduction Approaches in Diabetes: a Comparative Effectiveness (GRADE) Study cohort
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cardioprotective effects of insulin
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Target populations for novel triglyceride-lowering therapies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Development and validation of the Framingham Steatosis Index to identify persons with hepatic steatosis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
High-fidelity drug-induced liver injury screen using human pluripotent stem cell–derived organoids
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Improving fine-mapping by modeling infinitesimal effects
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A global reference for human genetic variation
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Molecular Signatures Database (MSigDB) hallmark gene set collection
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
clusterProfiler: an R package for comparing biological themes among gene clusters
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
STAR: ultrafast universal RNA-seq aligner
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
limma powers differential expression analyses for RNA-sequencing and microarray studies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

5 data/code links checked; 5 live.

datahttp://clinicaltrials.gov/ct2/show/NCT05483998LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
dataGEOLIVEHTTP 200
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299888
Resolves to GEO (data repository).
datahttps://www.finngen.fi/en/access_resultsLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datadbGaPLIVEHTTP 200
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002453.v1.p1
Resolves to dbGaP (data repository).
datahttps://www.finucanelab.org/dataLIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

MINORconsistencyAbstract
“38.5% in plasma TG and 61% in postprandial remnant cholesterol”
→ Ensure consistency with Table 1 values (e.g., -38.5% and -61.0%).
The abstract uses '61%' while Table 1 shows '-61.0%'.
MINORtypoMethods, Statistical analyses
“Pheonix WinNonlin”
→ Correct to 'Phoenix WinNonlin'.
Spelling error.
MINORclarityData availability
“are provided with this paper.”
→ Remove orphaned sentence fragment.
Incomplete sentence.
MINORconsistencyTable 1, VLDL cholesterol row
“P value versus placebo b — | — | 0.126 | 0.837 | 0.0058 | 0.148”
→ Use consistent decimal places (0.0058 vs 0.006 in RC row).
Minor inconsistency in decimal reporting.
MINORclarityAbstract
“placebo-adjusted reductions up to 38.5% in plasma TG and 61% in postprandial remnant cholesterol”
→ Specify that these are median percentage changes.
Clarify the metric for readers.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is generally robust, but readers should weigh the incomplete reporting of preclinical randomization/blinding/power, the lack of cell line authentication (especially the HepG2 misidentification), and the retrospective registration of the clinical trial. These issues do not invalidate the main conclusions but warrant caution and could justify an erratum or independent re-analysis of the affected experiments.

1.
HIGHrigor
Add explicit statements of randomization method and blinding for all preclinical animal studies in the Methods section.
Without these details, the preclinical results cannot be assessed for bias, which is a major reviewer concern.
2.
HIGHrigor
Include a priori power analysis or sample size justification for preclinical experiments in the Methods section.
The absence of power analysis undermines confidence in the statistical conclusions of the preclinical studies.
3.
HIGHrigor
Report IACUC approval numbers for all animal studies in the Methods section.
Missing IACUC statements are a reporting gap that reviewers and journals expect to be addressed.
4.
HIGHrigor
Provide authentication details (STR profiling) for cell lines used, especially HepG2, and state mycoplasma testing in the Methods section.
HepG2 is on the ICLAC misidentification register; without authentication, results may be attributed to the wrong cell type.
5.
HIGHreporting
Clarify the blinding status of the phase 1 clinical trial (single-blind, double-blind, or open-label) in the Methods section.
The trial is described as randomized and placebo-controlled but blinding is not stated, which is a key design detail.
6.
HIGHstatistics
Provide exact p-values (e.g., P = 0.032) instead of thresholds (P < 0.05) in figure legends and tables.
Threshold-only p-values are imprecise reporting and prevent readers from assessing the strength of evidence.
7.
MEDIUMrigor
Describe housing conditions for rodents (light cycle, temperature, enrichment) in the Methods section.
Housing conditions are a biological variable that can affect experimental outcomes and are currently not reported.
8.
MEDIUMreporting
Specify that the abstract's percentage reductions are median percentage changes.
Clarifying the metric improves interpretability and avoids ambiguity.
9.
MEDIUMcopyedit
Correct the typo 'Pheonix WinNonlin' to 'Phoenix WinNonlin' in the Methods section.
Spelling errors in software names can undermine credibility and should be fixed.
10.
MEDIUMcopyedit
Fix the orphaned sentence fragment in the Data availability section.
Incomplete sentences are a clarity issue that should be resolved.
11.
MEDIUMcopyedit
Ensure consistency in decimal places for p-values in Table 1 (e.g., 0.0058 vs 0.006).
Inconsistent decimal reporting is a minor but noticeable inconsistency.
12.
MEDIUMreporting
Clarify that the 61% reduction in remnant cholesterol is specifically for postprandial RC at the 12 mg dose in the abstract.
The abstract's 'up to 61%' could be misinterpreted as a general effect; specifying the context improves accuracy.
13.
LOWdata code
Consider depositing preclinical raw data in a public repository with a DOI, beyond Source Data.
Public deposition enhances reproducibility and is increasingly expected by journals.
14.
LOWreporting
Add a statement on whether the study followed ARRIVE guidelines for animal studies.
Explicit adherence to ARRIVE guidelines demonstrates commitment to rigorous animal research reporting.

Full text (91,838 chars · analyzed ~82%, head + tail)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

DOI

10.1038/s41591-025-04169-6

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20